RENOTEC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RENOTEC (RENOTEC).
Renotec is a direct renin inhibitor that binds to the active site of renin, inhibiting the conversion of angiotensinogen to angiotensin I, thereby reducing angiotensin II levels and lowering blood pressure.
| Metabolism | Primarily hepatic via CYP3A4; minor contributions from CYP2C19 and CYP2D6. Metabolites are inactive. |
| Excretion | Approximately 70% of the dose is excreted in urine as unchanged drug, and 20-30% via feces as metabolites; less than 5% is excreted unchanged in feces. |
| Half-life | Terminal elimination half-life is 12-15 hours; clinical context: supports once-daily dosing; half-life may be prolonged in renal impairment (creatinine clearance <30 mL/min). |
| Protein binding | Approximately 95% bound to plasma proteins, mainly albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is 0.2-0.3 L/kg, indicating moderate distribution into tissues; clinical meaning: limited extravascular distribution, predominantly in central compartment. |
| Bioavailability | Oral bioavailability is 40-50% due to first-pass metabolism; food does not significantly affect absorption. |
| Onset of Action | Oral: peak plasma concentration at 2-4 hours; clinical effect (blood pressure reduction) begins within 1-2 hours. |
| Duration of Action | Duration of antihypertensive effect is approximately 24 hours, allowing once-daily dosing; maximal effect may persist for 24-48 hours after discontinuation. |
Enalapril 5-40 mg orally once or twice daily; initial dose 5 mg once daily, titrate based on response.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-60 mL/min: reduce dose to 50%; GFR <30 mL/min: initial dose 2.5 mg daily; hemodialysis: 2.5 mg on dialysis days. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated. |
| Pediatric use | Children (1-16 years): 0.08 mg/kg up to 5 mg once daily; maximum 0.58 mg/kg or 40 mg daily. |
| Geriatric use | Initial dose 2.5 mg daily; monitor renal function and serum potassium; titrate slowly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RENOTEC (RENOTEC).
| Breastfeeding | Present in breast milk; M/P ratio not established. Potential for infant exposure; use only if benefit outweighs risk. Monitor infant for hypotension and renal impairment. |
| Teratogenic Risk | First trimester: Increased risk of congenital malformations, particularly cardiovascular and CNS defects. Second and third trimesters: Oligohydramnios, fetal renal dysfunction, skull ossification delay, and neonatal hypotension. |
| Fetal Monitoring |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
["Hypersensitivity to Renotec or any component","History of angioedema with previous renin-angiotensin system (RAS) inhibitor use","Pregnancy (category X)","Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment (eGFR <60 mL/min/1.73 m²)"]
| Precautions | ["Hypotension in volume-depleted patients","Hyperkalemia, especially in patients with renal impairment or on potassium-sparing diuretics","Renal impairment: Monitor serum creatinine and potassium","Angioedema: Discontinue immediately if occurs","Fetal toxicity: Avoid in pregnancy; discontinue if pregnancy is detected"] |
Loading safety data…
| Serial fetal ultrasound for oligohydramnios and renal function; maternal blood pressure weekly; fetal heart rate monitoring; periodic renal function tests (serum creatinine, BUN) and electrolytes. |
| Fertility Effects | No known direct effects on fertility; however, underlying condition may impact reproductive function. |